3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
32
Triple Negative Breast Neoplasms
26
Carcinoma, Transitional Cell
9
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
8
Urinary Bladder Neoplasms
7
Lung Neoplasms
4
Endometrial Neoplasms
3
Brain Neoplasms
3
Small Cell Lung Carcinoma
2
Salivary Gland Neoplasms
2
Ovarian Neoplasms
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Bladder Carcinoma
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Interventions
pembrolizumab
91
Blood Specimen Collection
43
Cyclophosphamide
37
Nivolumab
36
Bevacizumab
36
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
24
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Oxaliplatin
19
Docetaxel
19
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Biopsy
15
130-nm albumin-bound paclitaxel
15
Prednisone
14
Ipilimumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms
×
sacituzumab govitecan
×
1 year
×
Clear all
No trials found.